Business Context and Reporting Period
This Form 8-K, filed on November 6, 2013, reports events occurring on October 31 and November 1, 2013. Harvard Bioscience, Inc. completed the previously announced spin-off of its regenerative medicine business into an independent company named Harvard Apparatus Regenerative Technology, Inc. ("HART"). The transaction was executed via a distribution of HART common stock to Harvard Bioscience stockholders of record as of October 21, 2013.
Key Financial Metrics and Transaction Terms
The filing does not provide specific revenue, profit, cash flow, or debt figures for the reporting period. Key financial and structural terms of the transaction include:
- Distribution Ratio: One share of HART common stock was distributed for every four shares of Harvard Bioscience common stock outstanding.
- Fractional Shares: Fractional shares were not distributed; instead, they were aggregated, sold in the open market, and net cash proceeds were distributed pro rata to entitled holders.
- Transaction Costs: All third-party fees, costs, and expenses related to the separation and distribution were paid by Harvard Bioscience.
- Tax Status: The transaction is intended to qualify as a tax-free reorganization under Sections 355 and 368(a)(1)(D) of the Internal Revenue Code.
Material Changes Versus Prior Period
The primary material change is the structural separation of the Company into two independent entities. Harvard Bioscience retained all assets and liabilities not specifically transferred to HART (Excluded Assets/Liabilities), while HART assumed the regenerative medicine business assets and liabilities. Additionally, the Company's executive leadership changed effective at the time of the distribution:
- Departures: David Green (former President and Secretary) and Thomas McNaughton (former CFO and Treasurer) resigned to become CEO and CFO of HART, respectively.
- Appointments: Jeffrey A. Duchemin assumed the role of President (in addition to CEO), and Robert E. Gagnon assumed the roles of CFO, Treasurer, and Secretary.
Guidance, Outlook, and Post-Spin Agreements
Management entered into five definitive agreements to govern the relationship between the two companies post-separation:
- Separation and Distribution Agreement: Allocates assets, liabilities, and indemnification obligations. Includes provisions for settling intercompany accounts and adjusting employee equity awards to maintain intrinsic value (80% retained in Harvard Bioscience awards, 20% converted to HART awards).
- Intellectual Property Matters Agreement: Transfers HART-originated IP to HART. Establishes perpetual, royalty-free cross-licenses for existing IP. Grants exclusive, royalty-free licenses for new IP developed within five years in each other's respective fields. Includes 10-year non-compete and non-solicitation provisions.
- Product Distribution Agreement: Each company acts as the exclusive distributor for the other's products in their respective markets. HART is the exclusive manufacturer of bioreactors for Harvard Bioscience. Initial term is 10 years.
- Tax Sharing Agreement: Harvard Bioscience remains responsible for taxes on consolidated returns ending prior to the distribution. Post-distribution, each entity is responsible for its own taxes. Harvard Bioscience retains rights to tax refunds related to pre-distribution periods.
- Transition Services Agreement: Harvard Bioscience will provide administrative, HR, treasury, and IT services to HART on a transitional basis (generally one year) at cost without profit.
Investor Verification Checklist
- Verify the exact number of HART shares received based on the 1-for-4 distribution ratio and the handling of fractional share cash proceeds.
- Review the specific terms of the 10-year non-compete and non-solicitation clauses in the Intellectual Property Matters Agreement.
- Confirm the duration and cost structure of the Transition Services Agreement to assess ongoing operational dependencies.
- Examine the adjustment methodology for outstanding equity awards (options and RSUs) to ensure the 80/20 value split was applied correctly.
- Monitor future filings for the independent financial statements of HART and the updated financial position of Harvard Bioscience post-separation.